These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 34750815)

  • 41. Aducanumab Is Not Effective for Mild Cognitive Impairment or Mild Alzheimer Dementia and Has Major Safety Issues.
    Ebell MH
    Am Fam Physician; 2022 Oct; 106(4):462-463. PubMed ID: 36260879
    [No Abstract]   [Full Text] [Related]  

  • 42. Aducanumab for Alzheimer's disease: A regulatory perspective.
    Nisticò R; Borg JJ
    Pharmacol Res; 2021 Sep; 171():105754. PubMed ID: 34217830
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The Current State of Pharma and the FDA: Approval of a Dementia Drug as a Case in Point.
    Eiser AR
    Am J Med; 2021 Dec; 134(12):1442-1443. PubMed ID: 34256026
    [No Abstract]   [Full Text] [Related]  

  • 44. Aduhelm: The Best Hope for Alzheimer's Disease Patients or the Worst Decision the FDA Has Ever Made?
    Kurkinen M; Tran L
    J Alzheimers Dis; 2021; 84(3):969-971. PubMed ID: 34657888
    [No Abstract]   [Full Text] [Related]  

  • 45. Aducanumab Fails to Produce Efficacy Results Yet Obtains US Food and Drug Administration Approval.
    Angelo M; Ward L
    Popul Health Manag; 2021 Dec; 24(6):638-639. PubMed ID: 34516238
    [No Abstract]   [Full Text] [Related]  

  • 46. Lecanemab Gains FDA Approval for Early Alzheimer Disease.
    Larkin HD
    JAMA; 2023 Feb; 329(5):363. PubMed ID: 36652625
    [No Abstract]   [Full Text] [Related]  

  • 47. Aducanumab for Alzheimer disease: the amyloid hypothesis moves from bench to bedside.
    Musiek ES; Gomez-Isla T; Holtzman DM
    J Clin Invest; 2021 Oct; 131(20):. PubMed ID: 34651585
    [No Abstract]   [Full Text] [Related]  

  • 48. Controversial Alzheimer's drug approval could affect other diseases.
    Mullard A
    Nature; 2021 Jul; 595(7866):162-163. PubMed ID: 34193994
    [No Abstract]   [Full Text] [Related]  

  • 49. Aducanumab: What about the Patient?
    Petersen RC
    Ann Neurol; 2021 Sep; 90(3):334-335. PubMed ID: 34322904
    [No Abstract]   [Full Text] [Related]  

  • 50. [Not Available].
    Watt JA; Marple R; Hemmelgarn B; Straus SE
    CMAJ; 2021 Nov; 193(43):E1680-E1682. PubMed ID: 34725122
    [No Abstract]   [Full Text] [Related]  

  • 51. [Aducanumab and Alzheimer's disease: a critical reflection.].
    Vanacore N; Blasimme A; Canevelli M
    Recenti Prog Med; 2021; 112(7):495-498. PubMed ID: 34263875
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The Failure of Solanezumab - How the FDA Saved Taxpayers Billions.
    Sacks CA; Avorn J; Kesselheim AS
    N Engl J Med; 2017 May; 376(18):1706-1708. PubMed ID: 28467878
    [No Abstract]   [Full Text] [Related]  

  • 53. A Primer on the Evolution of Aducanumab: The First Antibody Approved for Treatment of Alzheimer's Disease.
    Mukhopadhyay S; Banerjee D
    J Alzheimers Dis; 2021; 83(4):1537-1552. PubMed ID: 34366359
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Recently Approved Alzheimer Drug Raises Questions That Might Never Be Answered.
    Rubin R
    JAMA; 2021 Aug; 326(6):469-472. PubMed ID: 34287610
    [No Abstract]   [Full Text] [Related]  

  • 55. The mechanism of action of the controversial drug; aducanumab and the story behind its speedy approval.
    Zainab A
    J Pak Med Assoc; 2022 May; 72(5):1019. PubMed ID: 35713088
    [No Abstract]   [Full Text] [Related]  

  • 56. Public opinion regarding U.S. Food and Drug Administration approval of aducanumab and potential policy responses: A nationally representative survey.
    DiStefano MJ; Alexander GC; Polsky D; Anderson GF
    J Am Geriatr Soc; 2022 Jun; 70(6):1685-1694. PubMed ID: 35129210
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Aducanumab and Accelerated Approval: Where Do We Go From Here?
    Kesselheim AS
    Clin Pharmacol Ther; 2022 Apr; 111(4):726-727. PubMed ID: 35174494
    [No Abstract]   [Full Text] [Related]  

  • 58. "Aducanumab" making a comeback in Alzheimer's disease: An old wine in a new bottle.
    Behl T; Kaur I; Sehgal A; Singh S; Sharma N; Makeen HA; Albratty M; Alhazmi HA; Felemban SG; Alsubayiel AM; Bhatia S; Bungau S
    Biomed Pharmacother; 2022 Apr; 148():112746. PubMed ID: 35231697
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Landmark Alzheimer's drug approval confounds research community.
    Mullard A
    Nature; 2021 Jun; 594(7863):309-310. PubMed ID: 34103732
    [No Abstract]   [Full Text] [Related]  

  • 60. Role of Aducanumab in the Treatment of Alzheimer's Disease: Challenges and Opportunities.
    Vaz M; Silva V; Monteiro C; Silvestre S
    Clin Interv Aging; 2022; 17():797-810. PubMed ID: 35611326
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.